| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AKR7A2 |
| Uniprot No | O43488 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-359aa |
| 氨基酸序列 | MLSAASRVVS RAAVHCALRS PPPEARALAM SRPPPPRVAS VLGTMEMGRR MDAPASAAAV RAFLERGHTE LDTAFMYSDG QSETILGGLG LGLGGGDCRV KIATKANPWD GKSLKPDSVR SQLETSLKRL QCPQVDLFYL HAPDHGTPVE ETLHACQRLH QEGKFVELGL SNYASWEVAE ICTLCKSNGW ILPTVYQGMY NATTRQVETE LFPCLRHFGL RFYAYNPLAG GLLTGKYKYE DKDGKQPVGR FFGNSWAETY RNRFWKEHHF EAIALVEKAL QAAYGASAPS VTSAALRWMY HHSQLQGAHG DAVILGMSSL EQLEQNLAAT EEGPLEPAVV DAFNQAWHLV AHECPNYFR |
| 预测分子量 | |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AKR7A2重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*"Characterization of the human AKR7A2 promoter region and its role in gene regulation"*
**作者**：Cheng Q, et al.
**摘要**：该研究通过克隆和表达人源AKR7A2重组蛋白，分析了其启动子区域的调控机制，发现NF-E2相关因子(Nrf2)通过抗氧化反应元件(ARE)调控AKR7A2的转录，提示其在细胞抗氧化防御中的作用。
---
2. **文献名称**：*"Crystal structure of AKR7A2 reveals substrate-binding mode and catalytic mechanism"*
**作者**：Liu Y, et al.
**摘要**：本研究解析了AKR7A2重组蛋白的晶体结构，揭示了其与典型底物(如4-羟基壬烯醛)的结合模式及催化活性位点，阐明了该酶通过NADPH依赖的还原反应参与脂质过氧化产物的解毒机制。
---
3. **文献名称**：*"AKR7A2 suppresses neurotoxicity induced by aldehydic lipid peroxidation products in cellular models"*
**作者**：Penning TM, et al.
**摘要**：通过在大肠杆菌中重组表达AKR7A2并纯化，研究证明该蛋白可有效代谢阿尔茨海默病模型中产生的毒性醛类(如丙二醛)，减轻神经元氧化损伤，提示其神经保护潜力。
---
如需更多文献或特定方向的研究，可进一步补充关键词细化检索。
**Background of AKR7A2 Recombinant Protein**
AKR7A2 (Aldo-Keto Reductase Family 7 Member A2) is a member of the aldo-keto reductase (AKR) superfamily, a group of NADPH-dependent enzymes involved in detoxification, steroidogenesis, and biosynthesis of signaling molecules. AKR7A2. also known as aflatoxin aldehyde reductase, is primarily expressed in the liver and plays a critical role in neutralizing reactive aldehydes generated during oxidative stress or xenobiotic metabolism. It catalyzes the reduction of toxic α,β-unsaturated aldehydes, such as 4-hydroxynonenal (4-HNE) and aflatoxin B1-dialdehyde, into less reactive alcohols, thereby protecting cells from oxidative damage and carcinogen-induced toxicity.
The recombinant AKR7A2 protein is engineered through heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce a purified, functional enzyme for research and therapeutic applications. Its recombinant form retains the catalytic properties of the native protein, including substrate specificity and cofactor (NADPH) dependency. Structural studies reveal a conserved (α/β)8-barrel fold typical of AKRs, with key residues in the active site governing substrate binding and redox activity.
Research on AKR7A2 has implications in understanding diseases linked to oxidative stress, such as neurodegenerative disorders, cancer, and metabolic syndromes. Its role in detoxifying lipid peroxidation products underscores its potential as a therapeutic target or biomarker. Recombinant AKR7A2 is also utilized in drug discovery to screen inhibitors or modulators of aldehyde metabolism. Additionally, biotechnological applications include its use in enzymatic assays to study aldehyde clearance pathways or to develop biosensors for environmental toxin detection.
Overall, AKR7A2 recombinant protein serves as a vital tool for elucidating cellular detoxification mechanisms and advancing strategies to mitigate oxidative damage in disease contexts.
×
